Enveda Biosciences raised $311 million in a Series E financing to advance its AI-driven drug discovery pipeline, including three oral drug candidates in clinical trials and two programs with positive early results reported earlier this year. The company said it will use the cash to push candidates into later-stage development and expand PRISM, its platform for mining nature’s chemistry. The round was led by Catalio Capital Management and includes major healthcare investors plus technology and growth-oriented backers, highlighting continued investor appetite for AI-native discovery models that translate into clinic-ready candidates. Enveda’s pipeline highlights three clinical efforts: ENV-294 for atopic dermatitis, ENV-308 focused on weight maintenance and metabolic health, and ENV-6949 targeting TL1A for inflammatory bowel disease. With this financing, Enveda is signaling a shift from platform validation toward execution in the clinic.